Socs3 Antibody

What is SOCS3 and why is it important to study with antibodies?

SOCS3 (Suppressor of Cytokine Signaling 3) is a critical negative regulator of cytokine signaling that inhibits the JAK/STAT pathway. In humans, the canonical SOCS3 protein has 225 amino acid residues with a molecular weight of approximately 24.8-30 kDa . SOCS3 is widely expressed with particularly high levels in heart, placenta, skeletal muscle, peripheral blood leukocytes, lung, and certain fetal tissues .

SOCS3 antibodies are essential research tools because they enable the detection and characterization of this important signaling regulator in various experimental settings. The protein's crucial role in immune homeostasis, inflammatory responses, and disease pathogenesis makes it a significant target for immunological and molecular biology research .

What applications are SOCS3 antibodies commonly used for?

SOCS3 antibodies are utilized across multiple research applications:

The choice of application depends on research objectives and specific experimental design considerations .

How do I select the appropriate SOCS3 antibody for my experiment?

Selection of an appropriate SOCS3 antibody should be based on:

• Target species reactivity: Confirm the antibody recognizes SOCS3 in your experimental model (human, mouse, rat, etc.)

• Application compatibility: Verify the antibody is validated for your intended application (WB, IHC, IF, etc.)

• Epitope recognition: Consider which domain of SOCS3 you need to target (full-length, N-terminal, C-terminal, SH2 domain)

• Clonality: Choose between monoclonal (higher specificity) or polyclonal (broader epitope recognition)

• Literature validation: Review publications citing the antibody for similar applications

• Validation data: Examine manufacturer's validation images and supporting data

For critical experiments, testing multiple antibodies from different sources/clones is recommended to ensure reproducibility and specificity .

What are the optimal conditions for detecting SOCS3 by Western blotting?

For optimal SOCS3 detection by Western blotting:

Sample preparation:

• Use RIPA buffer supplemented with protease inhibitors

• Include phosphatase inhibitors if studying phosphorylated SOCS3

• Load 30-50μg of total protein per lane

Electrophoresis conditions:

• Use 5-20% gradient SDS-PAGE gels

• Run at 70-90V for optimal separation

Transfer and detection:

• Transfer to nitrocellulose membrane at 150mA for 50-90 minutes

• Block with 5% non-fat milk in TBS for 1.5 hours at room temperature

• Incubate with anti-SOCS3 antibody at 0.5-1μg/ml overnight at 4°C

• Wash with TBS-0.1% Tween (3× for 5 minutes each)

• Use HRP-conjugated secondary antibody (1:10,000 dilution)

Expected results:

• SOCS3 typically appears at approximately 25-30kDa

• Multiple bands may indicate post-translational modifications

Note that SOCS3 expression is often low in resting cells but can be induced by cytokine treatment (e.g., IL-6, IFN-γ) .

How can I validate the specificity of SOCS3 antibodies in my experimental system?

Validating SOCS3 antibody specificity requires multiple approaches:

• Positive and negative controls:

  • Use cell lines with known SOCS3 expression (HeLa, Jurkat, U937, A549 are positive)

  • Include SOCS3 knockout/knockdown samples when possible

• Molecular weight verification:

  • Confirm band appears at expected molecular weight (24.8-30 kDa)

  • Be aware that post-translational modifications may alter apparent MW

• Peptide competition assay:

  • Pre-incubate antibody with immunizing peptide

  • Signal should be significantly reduced or eliminated

• Induction experiments:

  • Stimulate cells with known SOCS3 inducers (e.g., IL-6, IL-10)

  • Observe increased signal after treatment

• Overexpression studies:

  • Compare signal between wild-type and SOCS3-overexpressing cells

  • Use tagged SOCS3 constructs and detect with tag-specific antibodies

• Multiple antibody confirmation:

  • Use antibodies targeting different SOCS3 epitopes

  • Results should be consistent across antibodies

These validation steps ensure experimental findings are specific to SOCS3 rather than antibody artifacts .

What are the considerations for using SOCS3 antibodies in immunohistochemistry/immunofluorescence?

When performing IHC/IF with SOCS3 antibodies, consider:

Tissue preparation:

• Use fresh frozen sections or paraffin-embedded tissues

• For paraffin sections, heat-mediated antigen retrieval in citrate buffer (pH 6.0) is critical

Fixation considerations:

• 4% paraformaldehyde (10 min) is suitable for cultured cells

• Overfixation can mask epitopes and reduce signal

Blocking and permeabilization:

• Block with 5-10% normal serum from secondary antibody species

• Include 0.1-0.3% Triton X-100 or 0.1% PBS-Tween for permeabilization

Antibody incubation:

• Use 1-5μg/ml primary antibody (optimize for each antibody)

• Incubate overnight at 4°C for optimal results

Controls:

• Include secondary-only controls to assess background

• Use SOCS3-deficient tissues/cells as negative controls

• Cytokine-stimulated samples as positive controls

Expected pattern:

• SOCS3 typically shows cytoplasmic localization with potential nuclear signal

• Expression patterns vary significantly by tissue and activation state

Note that SOCS3 expression is often low in resting cells but increases upon cytokine stimulation, which may affect detection sensitivity .

How can SOCS3 antibodies be used to study protein-protein interactions in cytokine signaling?

SOCS3 antibodies enable sophisticated protein interaction analyses through:

Co-immunoprecipitation (Co-IP):

• Use SOCS3 antibodies conjugated to agarose/protein A/G beads

• Pull down SOCS3 and identify associated proteins (JAKs, cytokine receptors)

• Western blot for specific interaction partners

Proximity ligation assay (PLA):

• Combine SOCS3 antibody with antibodies against potential binding partners

• PLA signal indicates close proximity (<40nm) between proteins

• Allows visualization of interactions in intact cells

Time-course experiments:

• Monitor SOCS3 interactions following cytokine stimulation

• Map temporal dynamics of signaling complex assembly/disassembly

Domain-specific interactions:

• Use antibodies recognizing specific SOCS3 domains (SH2, KIR, SOCS box)

• Determine which domains are critical for particular interactions

Research shows SOCS3 interactions vary between:

• gp130-family cytokines (requiring direct receptor binding)

• γc-family cytokines (primarily through JAK interaction)

For example, experiments using truncated SOCS3 mutants revealed the SH2 domain (residues 46-142) is essential for interaction with p65 and subsequent degradation through the ubiquitin-proteasomal pathway .

What approaches can be used to study SOCS3-mediated protein degradation using antibodies?

To investigate SOCS3's role in protein degradation:

Ubiquitination assays:

• Immunoprecipitate target proteins (e.g., p65, JAKs)

• Probe with anti-ubiquitin antibodies

• Compare ubiquitination in presence/absence of SOCS3

Proteasome inhibition experiments:

• Treat cells with MG132 or other proteasome inhibitors

• Monitor target protein accumulation

• SOCS3-dependent degradation will be blocked by inhibitors

Domain mutation studies:

• Generate SOCS3 mutants lacking specific domains

• The SOCS box is critical for recruitment of E3 ubiquitin ligase complex

• Measure effects on target protein stability

Half-life determination:

• Perform cycloheximide chase experiments

• Compare degradation rates of target proteins with/without SOCS3

• Western blot at multiple timepoints to track protein levels

Research demonstrates SOCS3 mediates degradation of specific targets:

• p65 degradation occurs via ubiquitin-mediated proteasomal pathway

• SOCS3 causes degradation through SH2 domain interaction with p65

These methodologies help uncover SOCS3's dual mechanisms of action: direct inhibition of signaling molecules and promotion of their degradation .

How can SOCS3 antibodies be used to investigate T cell activation and differentiation?

SOCS3 antibodies enable detailed analysis of T cell biology:

Flow cytometry for cell-specific expression:

• Combine SOCS3 intracellular staining with surface markers

• Identify SOCS3 expression in specific T cell subsets

• Track changes during activation/differentiation

Th1/Th2 differentiation studies:

• SOCS3 is exclusively expressed in committed Th2 cells

• Monitor SOCS3 expression during T helper cell polarization

• Correlate with cytokine production profiles

CD28 costimulation analysis:

• SOCS3 inhibits CD28-mediated IL-2 production

• Use antibodies to track SOCS3 recruitment to CD28

• Study effect on downstream NF-κB activation

Treg development investigation:

• SOCS3 interferes with Foxp3+ regulatory T cell generation

• Examine SOCS3 expression during Treg differentiation

• Correlate with IL-2 signaling components

IL-7-dependent T cell development:

• SOCS3 impairs thymic T cell development

• Use antibodies to study SOCS3 expression during thymocyte maturation

• Correlate with IL-7 signaling components

Research shows SOCS3 not only suppresses gp130 family cytokines but also inhibits γc cytokine signaling, affecting T cell development, homeostasis, and differentiation .

Why might SOCS3 detection by Western blot be challenging and how can I optimize it?

SOCS3 detection challenges and solutions:

Low expression levels:

• SOCS3 is often expressed at low basal levels

• Pre-treat cells with inducers (IL-6, IL-10, TNF-α) before lysis

• Enrich SOCS3 by immunoprecipitation before Western blotting

Rapid degradation:

• SOCS3 has a short half-life (~30-120 minutes)

• Include proteasome inhibitors (MG132) in lysis buffer

• Process samples quickly and maintain at 4°C

Non-specific bands:

• SOCS3 antibodies may cross-react with related proteins

• Use SOCS3 knockout/knockdown controls

• Try antibodies targeting different epitopes

Post-translational modifications:

• Phosphorylation alters SOCS3 mobility on gels

• Consider phosphatase treatment of lysates

• Use phospho-specific antibodies when studying modifications

Antibody selection:

• Test multiple antibodies from different vendors/clones

• Monoclonal antibodies typically provide higher specificity

• Verify reactivity with your species of interest

Detection system:

• Use high-sensitivity ECL substrates

• Consider fluorescent secondary antibodies for better quantification

• Longer exposure times may be necessary

These optimizations significantly improve SOCS3 detection reliability and reproducibility in Western blot applications.

How do I reconcile contradictory findings about SOCS3 expression in my experimental system?

When facing contradictory SOCS3 expression results:

Biological variability considerations:

• SOCS3 expression varies dynamically with cellular activation state

• Expression can differ between cell types even within the same tissue

• Expression changes rapidly in response to stimuli (temporal dynamics)

Technical reconciliation strategies:

• Time-course analysis:

  • SOCS3 expression changes rapidly after stimulation

  • HIV-1 infection shows biphasic regulation (early downregulation, late upregulation)

  • Monitor expression at multiple timepoints (minutes to hours)

• Cell-specific expression analysis:

  • Use cell sorting or single-cell approaches

  • Combine with histological techniques for tissue context

  • Different cell populations may show opposing regulation

• Methodological cross-validation:

  • Compare protein (Western blot) vs. mRNA (qPCR) levels

  • Assess with multiple antibodies recognizing different epitopes

  • Use complementary techniques (flow cytometry, IHC)

• Stimulus-specific responses:

  • Different cytokines induce distinct SOCS3 expression patterns

  • TCR/CD28 stimulation affects SOCS3 differently than cytokines

  • Control stimulation conditions precisely

• Examine post-translational regulation:

  • Protein levels may not correlate with activity due to modifications

  • Assess phosphorylation state using phospho-specific antibodies

  • Consider protein stability and degradation

Understanding these factors helps resolve apparently contradictory findings about SOCS3 expression and function .

What controls should be included when studying SOCS3 in disease models?

Comprehensive controls for SOCS3 studies in disease models:

Genetic controls:

• SOCS3 knockout/knockdown (conditional models preferred due to embryonic lethality)

• SOCS3 transgenic overexpression models

• Littermate controls to minimize genetic background effects

Treatment controls:

• Known SOCS3 inducers (IL-6, IL-10, leptin) as positive controls

• Time-course samples to capture expression dynamics

• Pathway inhibitors (JAK inhibitors) to confirm signaling specificity

Cell/tissue-specific controls:

• Cell types with known SOCS3 expression patterns:

  • High: committed Th2 cells, cytokine-stimulated macrophages

  • Low: resting T cells, unstimulated epithelia

• Comparison between affected and unaffected tissues within same subject

Domain-specific functional controls:

• SOCS3 mutants lacking specific functional domains:

  • SH2 domain (aa 46-142): receptor/protein binding

  • KIR domain (aa 22-29): JAK inhibition

  • SOCS box (aa 186-225): protein degradation

Disease-specific considerations:

• Compare disease state vs. healthy controls

• Include samples representing different disease stages/severity

• Consider treatment effects on SOCS3 expression

Technical validation controls:

• Antibody specificity controls (peptide competition)

• Secondary antibody-only controls

• Isotype controls for flow cytometry

These comprehensive controls strengthen experimental interpretations and facilitate comparison between different disease models .

How can SOCS3 antibodies contribute to understanding cytokine regulation during infectious diseases?

SOCS3 antibodies reveal critical insights into infection responses:

Viral infection studies:

• HIV-1 differentially regulates SOCS3 during infection cycle:

  • Early phase: SOCS3 downregulation

  • Late phase: SOCS3 upregulation (mediated by HIV-1 Tat)

• This biphasic regulation affects antiviral responses at different stages

Bacterial infection monitoring:

• SOCS3 expression patterns help distinguish between:

  • Acute vs. chronic bacterial infections

  • Pathogenic vs. commensal bacteria interactions

  • Effective vs. ineffective immune responses

Infection-specific signaling analysis:

• SOCS3 regulates both JAK/STAT and NF-κB pathways:

  • Direct JAK inhibition through KIR domain

  • p65 degradation via ubiquitin-proteasomal pathway

• Dual targeting allows fine-tuning of inflammatory responses

Experimental approaches:

• Time-course studies: Track SOCS3 expression during infection progression

• Cell-specific analysis: Identify which immune cells upregulate SOCS3

• Signaling cascade examination: Determine which pathways are affected

• Pathogen-host interaction analysis: Study how pathogens manipulate SOCS3

Understanding these mechanisms can reveal how pathogens exploit SOCS3 to evade immunity and suggest novel therapeutic approaches targeting cytokine regulation during infections .

What is the role of SOCS3 in T cell function and how can antibodies help elucidate these mechanisms?

SOCS3 antibodies reveal complex roles in T cell biology:

Cytokine signaling regulation:

• SOCS3 suppresses not only gp130 cytokines but unexpectedly inhibits γc cytokines

• This expanded suppression profile affects:

  • IL-7-dependent thymic development

  • IL-2-mediated Treg cell generation

  • T cell homeostasis in peripheral tissues

CD28 costimulation modulation:

• SOCS3 inhibits CD28-mediated IL-2 production through:

  • Interaction with phosphorylated CD28 via SH2 domain

  • Inhibition of NF-κB activation following CD28 costimulation

  • Specifically affecting CD28RE region within IL-2 promoter

T helper cell differentiation:

• SOCS3 is exclusively expressed in committed Th2 cells

• Differential SOCS3 expression affects:

  • Cytokine production profiles (Th1 vs. Th2)

  • Dependence on CD28 costimulation (IL-4/IL-5 vs. IFN-γ/IL-2)

  • Susceptibility to different immunomodulatory strategies

Experimental approaches with antibodies:

• Flow cytometry: Track SOCS3 expression in T cell subsets

• Chromatin immunoprecipitation: Study SOCS3 binding to IL-2 promoter

• Signaling analysis: Monitor STAT5 phosphorylation in presence/absence of SOCS3

• Protein interaction studies: Examine SOCS3-CD28 complex formation

These findings expand our understanding of how SOCS3 balances T cell activation, differentiation, and function in both health and disease .

How can SOCS3 antibodies be utilized in the development of new therapeutic approaches?

SOCS3 antibodies facilitate therapeutic development through:

Biomarker identification:

• Monitor SOCS3 expression levels as indicators of:

  • Disease progression

  • Treatment response

  • Inflammation severity

  • Immune dysregulation

Target validation studies:

• Confirm SOCS3's role in disease processes:

  • Inflammatory diseases (elevated in active lesions)

  • Autoimmune conditions (dysregulated in affected tissues)

  • Cancer (altered expression affects oncogenic signaling)

  • Metabolic disorders (modulates insulin and leptin signaling)

Therapeutic mechanism investigation:

• Determine how potential therapeutics affect SOCS3:

  • JAK inhibitors may alter SOCS3 feedback loops

  • Cytokine-targeting biologics influence SOCS3 expression

  • Small molecule modulators may target SOCS3 interactions

Methodology for therapeutic development:

• Expression profiling: Identify disease-specific SOCS3 patterns

• Interaction screening: Find compounds disrupting pathological SOCS3 interactions

• Functional assessment: Evaluate effects on cytokine signaling pathways

• Cell-specific targeting: Develop approaches to modulate SOCS3 in specific cell types

SOCS3 presents a valuable therapeutic target due to its central role in balancing cytokine responses, particularly in conditions characterized by chronic inflammation or immune dysregulation .